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tion (FDA) for rifapentine and the Good Clinical Practice
(GCP) standards of the International Conference on Har-
monization of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH). Clinical trial ex-
perts reviewed the protocol and costs were assessed based
on the Resource Based Relative Value Scale (RBRVS), ex-
pert opinion, and published prices for materials and ser-
vices. We constructed a model that summarized costs per
patient, per trial site, and per trial to implement the proto-
col. Entering the number of patients to be assessed, num-
ber of trial sites, number of trials, and anticipated drop out
rates generated estimated costs. The model calculated the
cost for all patients to complete the trial, costs associated
with screening patients who drop out immediately, and
savings that may be realized from patients dropping out
during the trial. These figures generated lower and upper
trial cost estimates. A 15% drop out rate at screening and
a 15% drop out rate during the trial was assumed.
RESULTS: For 850 to 1,000 patients to complete a Phase
III trial, 1,176 patients will need to be screened. The esti-
mated total cost (2000 US dollars) is between $22.3 mil-
lion and $22.6 million.
CONCLUSIONS: A Phase III clinical trial for a new pul-
monary TB drug will cost between $22.3 million and
$22.6 million, assuming a drop out rate no greater than
15% at screening and 15% over the course of the trial.
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OBJECTIVE: To assess the cost-effectiveness of Aldara
(Imiquimod) 5% topical cream versus other therapies for
the management of external genital warts (EGWs) in a
Dutch treatment environment.
METHODS: An economic model is presented that uti-
lizes a two-stage therapy sequence. Choice of initial and
subsequent therapy was based on the results of a recently
completed chart review of three dermatology clinics in
the Netherlands. This chart review provided valuable
guidance regarding treatment switching, resources used
(i.e. average number of patient visits) and costs associ-
ated with the management of EGWs. Sustained clearance
rates were incorporated into the economic model based
on published literature of key clinical trial results. Cost-
ing was based on nationally available cost estimates for
the Netherlands as costs based on chart reviews were site
specific and hence were not appropriate for use.
RESULTS: Estimated average costs per successful clearance
for Aldara plus cryotherapy were 1,128 DFL (€512) com-
pared with 1,455 DFL (€660) for the next most cost-effec-
tive therapy sequence—Condyline (first line) plus cryother-
apy (second line). In terms achieving the therapeutic target
of 50% clearance, only sequences in which Aldara was used
as first line therapy achieved this.
CONCLUSION: The results of the cost-effectiveness
analysis demonstrated that Aldara (as first line therapy)
plus cryotherapy (second line) was the most cost-effective
therapy sequence in the Netherlands.
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OBJECTIVE: To estimate costs and benefits of a preven-
tive influenza vaccination in a group of employees of Snam-
progetti (an Eni-group company), to define a scheme of
cost-benefit analysis to be used for other strategies of vacci-
nation and in other contexts.
METHODS: In an observational study conducted from
October 1999 to June 2000, 153 employees (about 10%
of the whole staff of Snamprogetti) voluntarily received
the vaccine, and were compared to 153 non-vaccinated
employees working in the same context and matched for
age and gender. The outcome was evaluated by checking
absentee records from the personnel department and de-
termining the causes, including influenza. Costs and ben-
efits of the influenza vaccination from the Snamprogetti
point of view were subsequently calculated.
RESULTS: The influenza vaccination strategy reduced
absence from work by 77% and has decreased the loss of
working days by 82%. The relationship between the ben-
efits of the vaccination strategy (less working days lost)
and its cost was 12.12. Convenience also becomes evi-
dent following sensitivity analysis, which considered the
mean cost of a working day for the employees enrolled,
and showed that the cost-benefit ratio was 9.45.
CONCLUSIONS: The results of this study suggest that
implementation of an influenza vaccination strategy in
Snamprogetti was cost effective. The cost-benefit analysis
used in this study could also be used for other vaccina-
tion strategies and in other contexts.
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OBJECTIVES: Influenza is a major cause of illness, pro-
ductivity loss, and work absenteeism among healthy work-
ing adults aged between 25 and 64 years. This group is not
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included in the national Dutch influenza vaccination pro-
gram, that encompasses the elderly of 65 years and older.
The objective of this study is to estimate the cost and ben-
efits of vaccinating healthy working adults aged 25 to 64
years against influenza.
METHODS: Our cost-benefit analysis includes the direct
and indirect costs associated with vaccination as well as
the direct and indirect costs avoided by vaccination. The
underlying model links influenza incidence to health-care
resource use, work absenteeism and productivity loss.
Health-care resource use was specified for general practi-
tioner visits, hospitalizations and drugs. Clinical and eco-
nomical parameter estimates were derived from pub-
lished literature and Dutch registry data.
RESULTS: Vaccinating healthy working adults aged 25
to 44 years costs € 0,39 per person per year. Vaccinating
persons aged 45 to 64 years saves € 1,51 per person per
year. On the population level, vaccinating persons aged
25–44 years costs about € 1,4 million per year, vaccinat-
ing persons aged 45-64 years saves about € 2,3 million
per year. On average, vaccinating healthy working adults
saves € 0,9 million. The indirect costs prevented prima-
rily determine the cost-benefit outcome of vaccination for
healthy working adults.
CONCLUSIONS: Influenza vaccination of healthy work-
ing adults is cost saving. These findings support routine
vaccination for this group, from the employer’s perspective.
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OBJECTIVES: Toenail onychomycosis is the most com-
mon nail fungal infection. If left untreated, it can evolve
into a more severe stage that can involve the matrix. The
clinical management of patients remains constraining and
long. In addition, relapses occur frequently after antifun-
gal treatment. This has significant socio-economic im-
pact. Combining topical and oral antifungals can increase
cure rates and decrease treatment duration. The Ony-
choTree project aims at providing an evaluation tool to
estimate economic consequences of the management of
severe toenail onychomycosis in Europe.
METHODS: The methodology for OnychoTree develop-
ment follows a rigorous stepwise design to obtain an inter-
national model, valid for use across 17 countries: 1) an ex-
tensive literature review of international data on toenail
onychomycosis; 2) the design of a core clinical manage-
ment-decision tree; 3) the validation and completion of the
core model (treatment patterns and medical resource use)
by an expert panel of 12 dermatologists from six countries;
4) expansion and validation of the model to 11 additional
countries through advisory panel interviews assessing na-
tional specificities (disease management and associated
costs); 5) a meta-analysis of efficacy rates from relevant
clinical trials of antifungals; 6) cost-effectiveness analyses.
RESULTS: The initial common model was designed from
the available international literature. The expert panel
clinicians confirmed their interest for: 1) a clinical man-
agement model, and 2) cost-effectiveness evaluation in-
cluding new combination therapies. They requested ad-
aptations to reflect country-specific medical practice.
After adaptation, they validated the core European phar-
macoeconomic model. Advisory panel interviews con-
firmed these results, focusing on the need for country-
specific analyses based on a common decision tree.
CONCLUSIONS: Cost-effectiveness analyses including
the 17 country-specific data will be performed with the
final model. These European results will make both med-
ical professionals and the public aware of the possible im-
provement in health-care resource use for the manage-
ment of severe toenail onychomycosis.
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OBJECTIVE: We conducted a cost-benefit analysis of
two approaches to manage a regional outbreak of sero-
group C meningococcal disease (MCD): 1. a planned
mass immunization program (MIP) of 2,000,000 Quebec
residents aged 2 months to 20 years, that would be im-
plemented in September 2001; 2. an emergency MIP im-
plemented at the peak of subsequent outbreaks.
METHODS: As a reference case, we used the scenario
that occurred in Quebec in 1991—several targeted re-
gional vaccination programs were implemented in an at-
tempt to ward off a more widespread outbreak of MCD.
Unfortunately, at the end of 1992, public-health authori-
ties had to implement a province-wide emergency MIP.
We assessed the benefit of the programs using epidemio-
logical data from the previous cycle of MCD in Quebec.
Benefits included the number of new MCD cases pre-
vented by the administration of Menjugate™ and their
associated hospital and societal costs due to premature
mortality and related morbidity. Costs included acquisi-
tion and administration cost of the conjugate vaccine,
clerical, physician and health-services costs, and those re-
lated to lost productivity. We conducted the analysis in a
societal perspective assuming Quebec would face a simi-
lar epidemiological situation in 2001 as the one that
started in 1991. All costs were transformed into 2001
Canadian dollars at an annual inflation rate of 3%.
RESULTS: Over a 12-month period, a planned MIP
would prevent 127 new cases (18 deaths, 24 major com-
plications) while saving $15.0 million in direct costs to
